Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(17): 2019-2028 [PMID: 31114130 DOI: 10.3748/wjg.v25.i17.2019]
Corresponding Author of This Article
Jian-Gao Fan, MD, PhD, Chief Doctor, Professor, Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, 1665 Kong Jiang Road, Shanghai 200092, China. fanjiangao@xinhuamed.com.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Opinion Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 7, 2019; 25(17): 2019-2028 Published online May 7, 2019. doi: 10.3748/wjg.v25.i17.2019
Microbial metabolites in non-alcoholic fatty liver disease
Da Zhou, Jian-Gao Fan
Da Zhou, Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai Institute of Liver Disease, Shanghai 200032, China
Jian-Gao Fan, Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai 200092, China
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Supported byNational Key Research and Development Plan ‘ Precision Medicine Research’ , No. 2017YFSF090203; the National Natural Science Foundation of China, No. 81470840, No. 81873565, and No. 81800510; and Shanghai Sailing Program, No. 18YF1415900.
Conflict-of-interest statement: No potential conflicts of interest.
Corresponding author: Jian-Gao Fan, MD, PhD, Chief Doctor, Professor, Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, 1665 Kong Jiang Road, Shanghai 200092, China. fanjiangao@xinhuamed.com.cn
Telephone: +86-21-25077340 Fax: +86-21-63846590
Received: February 21, 2019 Peer-review started: February 22, 2019 First decision: March 20, 2019 Revised: March 25, 2019 Accepted: March 29, 2019 Article in press: March 30, 2019 Published online: May 7, 2019 Processing time: 74 Days and 17.8 Hours
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) is rising exponentially worldwide. The spectrum of NAFLD includes non-alcoholic fatty liver, non-alcoholic steatohepatitis, liver cirrhosis, and even hepatocellular carcinoma. Evidence shows that microbial metabolites play pivotal roles in the onset and progression of NAFLD. In this review, we discuss how microbe-derived metabolites, such as short-chain fatty acids, endogenous ethanol, bile acids and so forth, contribute to the pathogenesis of NAFLD.
Core tip: Non-alcoholic fatty liver disease (NAFLD) is a global epidemic metabolic disease lacking effective therapeutic strategies and the internal pathogenesis is still uncertain. Gut microbiota-derived metabolites have attracted much attention for its association with the onset and progression of NAFLD. In this review, we mainly elucidate the diverse roles of microbe-derived metabolites in the development of NAFLD, which is conducive to better understanding the biological functions of microbial metabolites in NAFLD via the gut-liver axis and facilitating the excavation of potential therapeutic approaches for NAFLD.
